Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=cjc-1295,sermorelin,tesamorelin

Side-by-side comparison of CJC-1295, Sermorelin, Tesamorelin
Identity
	CJC-1295	Sermorelin	Tesamorelin
Class	Growth hormone-releasing hormone (GHRH) analogue. Supplied in two chemically distinct forms	GHRH analogue — human GHRH (1-29) amide	Stabilised GHRH analogue — human GHRH(1-44) amide, N-terminally acylated
Also listed as	CJC-1295 DAC, DAC:GRF, Modified GRF (1-29), Mod GRF 1-29	Geref, GRF(1-29)NH2, Sermorelin acetate	Egrifta, TH9507, Tesamorelin acetate
Molecular formula	With DAC: C165H269N47O46 · Without DAC: C152H252N44O42	C149H246N44O42S	C221H366N72O67S
Molecular weight	With DAC: 3647.2 g/mol · Without DAC: 3367.9 g/mol	3357.9 g/mol	5136 g/mol
CAS	With DAC: 446262-90-4 · Without DAC: 863288-34-0	86168-78-7	218949-48-5
PubChem CID	91971820 (with DAC) · 56841945 (without DAC)	16132413	16137828
Sequence length	Described structurally, not as a residue list	29 residues	Described structurally, not as a residue list
Data caveat	“CJC-1295” is used commercially for both the DAC and non-DAC molecules, and vendor CAS assignments frequently conflict. Full caveat	None recorded	None recorded
United States regulatory status
Status	No FDA-approved product	Formerly approved — discontinued	FDA-approved drug substance
FDA application	None recorded	NDA 020443 (GEREF) — marketing status: discontinued	BLA 022505 (EGRIFTA)
Compounding	FDA bulk-substance nomination withdrawn; safety concerns remain published.	No FDA compounding entry recorded	No FDA compounding entry recorded
WADA	Named at S2.2.4 among GHRH analogues. Prohibited at all times; non-Specified.	Named at S2.2.4 among GHRH analogues. Prohibited at all times; non-Specified.	Named at S2.2.4 among GHRH analogues. Prohibited at all times; non-Specified.
Research profile
Research purpose	Long-acting GHRH analogue research	No plain-English profile recorded	Visceral adiposity in HIV lipodystrophy
Proposed mechanism	Acts at pituitary GHRH receptors to stimulate GH release. The DAC form carries a maleimidopropionyl group that binds albumin and prolongs exposure; the non-DAC form does not.	No plain-English profile recorded	Binds pituitary GHRH receptors and stimulates pulsatile endogenous growth hormone release, which in turn raises IGF-1 and affects visceral adipose tissue.
Human evidence	No approved product. Published human data are limited to early pharmacology; no Phase 3 efficacy programme is indexed.	No plain-English profile recorded	Randomised trials in HIV-associated lipodystrophy support the approved indication. It is not approved for general weight loss or cosmetic fat reduction.
Evidence tier	Preclinical models; no human efficacy trial indexed	No plain-English profile recorded	Approved drug product in the United States
Known safety concerns	FDA's withdrawn-nomination entry references serious adverse events reported with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. Named on the WADA Prohibited List as a GHRH analogue. Vendor CAS assignments for the two forms frequently conflict; identity must be checked by formula, not name.	No plain-English profile recorded	The label carries warnings, including effects on glucose and IGF-1 and an increased risk of neoplasms in certain patients. Injection-site reactions and fluid retention are described in the labelling. Growth-hormone axis effects require clinical monitoring; this record is not a safety assessment.
Evidence gaps	Which form any given product actually contains. Controlled human efficacy and long-term safety. The basis for combining it with a ghrelin-receptor agonist.	No plain-English profile recorded	Long-term outcomes outside the approved population. Whether visceral-fat changes in other populations translate into clinical benefit.
Head-to-head evidence	No published head-to-head trial against tesamorelin, sermorelin or ipamorelin.	No plain-English profile recorded	No published head-to-head trial against ipamorelin or CJC-1295. They act at different receptors and have different regulatory status.
Named pathways	GHRH receptor · Pituitary GH release · IGF-1 · Albumin binding	No plain-English profile recorded	GHRH receptor · Pituitary GH release · IGF-1 · Visceral adipose tissue
Evidence on file
Records	5Open evidence file	3Open evidence file	3Open evidence file
Human-interventional records	2	0	1
Human-observational records	0	0	0
Animal records	0	0	0
In-vitro records	0	0	0
Reviews	1	1	0
Regulatory documents	2	2	2
Earliest indexed	2006	1997	2007
Latest indexed	2026	2026	2026

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.

Overlapping pathways

Named in the mechanism discussion for at least two of these compounds: GHRH receptor · IGF-1 · Pituitary GH release.

Shared biology is not shared evidence. No claim of synergy is made here, and overlapping pathways do not mean the compounds have been studied together.